HC Wainwright reissued their buy rating on shares of TG Therapeutics (NASDAQ:TGTX – Free Report) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $78.00 price objective on the biopharmaceutical company’s stock.
Several other equities research analysts have also commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. B. Riley Financial raised their target price on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Bank of America raised their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $63.00.
Check Out Our Latest Report on TG Therapeutics
TG Therapeutics Stock Down 0.3%
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same quarter last year, the company earned $0.17 EPS. Equities analysts predict that TG Therapeutics will post 0.92 EPS for the current fiscal year.
Institutional Trading of TG Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Danske Bank A S purchased a new stake in shares of TG Therapeutics during the 3rd quarter valued at approximately $25,000. EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the period. Hantz Financial Services Inc. grew its position in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares during the period. Truvestments Capital LLC increased its stake in TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in TG Therapeutics during the fourth quarter worth $52,000. Institutional investors and hedge funds own 58.58% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Featured Stories
- Five stocks we like better than TG Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
